Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | MAX | P61244 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | GPR3 | P46089 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22534716 | 0.74 | MAPK10 (0.50) | MAPK10RIPK1MYCMAXMAOA | |
| SCHEMBL22534717 | 0.73 | KDM4E (0.56) | MAPK10RIPK1MYCMAXMAOA | |
| SCHEMBL11097190 | 0.72 | KDM4E (0.47) | MAOAGPR3KDM4EHPGDHSD17B10 | |
| SCHEMBL26688602 | 0.71 | LMNA (0.51) | MAPK10KDM4EKMT2ATSHRMEN1 | |
| SCHEMBL3238859 | 0.70 | GPR3 (0.45) | MAPK10RIPK1MYCMAXMAOA | |
| SCHEMBL29588824 | 0.70 | MAPK10 (0.42) | MAPK10RIPK1MYCMAXMAOA | |
| SCHEMBL4495841 | 0.70 | MAPK10 (0.42) | MAPK10RIPK1MYCMAXMAOA | |
| SCHEMBL19445500 | 0.70 | GPR3 (0.58) | MAPK10RIPK1MYCMAXMAOA | |
| SCHEMBL534925 | 0.69 | LMNA (0.48) | KDM4EKMT2ATSHRMEN1USP2 | |
| SCHEMBL4507428 | 0.69 | MAPK10 (0.45) | MAPK10RIPK1MYCMAXMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115415064-A | System for applying coating compositions using high transfer efficiency applicators and corresponding method | 艾仕得涂料系统有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-114950776-A | Coating compositions applied using high transfer efficiency applicators and methods and systems thereof | 艾仕得涂料系统有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-111432935-B | System for applying coating compositions using high transfer efficiency applicators and corresponding method | 艾仕得涂料系统有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114918063-A | System for applying a coating composition using a high transfer efficiency applicator, coating and corresponding method | 艾仕得涂料系统有限责任公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114904681-A | Coating compositions applied using high transfer efficiency applicators and methods and systems thereof | 艾仕得涂料系统有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114602682-A | System for applying coating compositions using high transfer efficiency applicators and corresponding method | 艾仕得涂料系统有限责任公司 | 2022-06-10 | — | — | CN | disclosed |
| US-6932961-B1 | Oxazinocarbazoles for the treatment of CNS diseases | PHARMACIA & UPJOHN COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-6932961-B1 | Oxazinocarbazoles for the treatment of CNS diseases | PHARMACIA & UPJOHN COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-6932961-B1 | Oxazinocarbazoles for the treatment of CNS diseases | PHARMACIA & UPJOHN COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1495031-A1 | LABELED OXAZINOCARBAZOLES AS DIAGNOSTIC AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6448397-B1 | TREATING CENTRAL NERVOUS SYSTEM DISEASES WITH MODULATION OF 5-HT ACTIVITY; ADRENERGIC, DOPAMINERGIC, AND SEROTONERGIC NEUROTRANSMITTERS; PSYCHOSIS, PARAPHRENIA, DEPRESSION, MANIA, SCHIZOPHRENIA, ANXIETY, MIGRAINE HEADACHE, DRUG ADDICTION | PHARMACIA & UPJOHN COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6448397-B1 | TREATING CENTRAL NERVOUS SYSTEM DISEASES WITH MODULATION OF 5-HT ACTIVITY; ADRENERGIC, DOPAMINERGIC, AND SEROTONERGIC NEUROTRANSMITTERS; PSYCHOSIS, PARAPHRENIA, DEPRESSION, MANIA, SCHIZOPHRENIA, ANXIETY, MIGRAINE HEADACHE, DRUG ADDICTION | PHARMACIA & UPJOHN COMPANY | 2002-09-10 | — | — | US | disclosed |
| CN-1361781-A | Oxazinocarbazoles for the treatment of CNS diseases | UPJOHN CO (US) | 2002-07-31 | — | — | CN | disclosed |
| CN-1361781-A | Oxazinocarbazoles for the treatment of CNS diseases | UPJOHN CO (US) | 2002-07-31 | — | — | CN | disclosed |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-06-06 | — | — | US | disclosed |
| EP-1200447-A1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1200447-A1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2002008178-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001009142-A1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009142-A1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | HTR6, HTR5A, HTR2C | MAPK10 4622/4885RIPK1 4084/4885MYC 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.